Surgery of highly eloquent gliomas primarily assessed as non-resectable: Risks and benefits in a cohort study

Keyphrases

• Non-resectable 100%
• Glioma 100%
• Intraoperative Neuromonitoring 100%
• Surgical Resection 66%
• Specialized Center 66%
• Motor Evoked Potential 66%
• Awake Surgery 66%
• Intraoperative Brain Mapping 66%
• Quality of Life 33%
• Tumor 33%
• Postoperative Outcomes 33%
• Motor Deficits 33%
• Insula 33%
• Low Dose Rate 33%
• Resection 33%
• Low-grade Glioma 33%
• After Surgery 33%
• Intraoperative Monitoring 33%
• Treatment Choice 33%
• Gross Total Resection 33%
• Glioblastoma 33%
• Surgical Strategy 33%
• I(2) 33%
• Karnofsky Performance Status 33%
• Brain Monitoring 33%
• Median Survival 33%
• Surgery Rates 33%
• Progression-free 33%
• Anaplastic Astrocytoma 33%
• Pilocytic Astrocytoma 33%
• Language Impairment 33%
• WHO Grade IV 33%
• WHO Grade I 33%
• Surgery Risk 33%
• Rolandic 33%
• Diffuse Astrocytoma 33%
• Perisylvian Cortex 33%
• Cortical Regions 33%
• WHO Grade II 33%
• WHO Grade III 33%
• Supratentorial Glioma 33%

Medicine and Dentistry

• Cohort Analysis 100%
• Ganglioglioma 100%
• Neuromonitoring 80%
• Surgery 80%
• Glioblastoma 40%
• Motor Evoked Potential 40%
• Brain Mapping 40%
• Quality of Life 20%
• Neoplasm 20%
• Karnofsky Performance Status 20%
• Progression Free Survival 20%
• Oligoastrocytoma 20%
• Insula 20%
• Pilocytic Astrocytoma 20%